

## Public Disclosure Statement

### A Joint Working Project partnership between Bristol-Myers Squibb Pharmaceuticals Limited (BMS) on behalf of the BMS-Pfizer Alliance and Chelsea and Westminster Foundation Trust

Name of Project:	Title: <b>Maximising opportunities to identify patients at risk of AF through the deployment of the PULsE AI algorithm and the implementation of a 'targeted' screening and diagnosis pathway.</b>
Project Overview:	<p>The aim of the joint working project is to:</p> <p><b>Maximise opportunities to detect and diagnose patients at risk of atrial fibrillation through the effective deployment and integration of the Machine Learning algorithm within an enhanced screening and diagnosis clinical pathway.</b></p> <p>Chelsea and Westminster NHS Foundation Trust seek to work in partnership with BMS on behalf of BMS-Pfizer Alliance to deliver a joint working project. The joint working contracted agreement will be between BMS on behalf of BMS-Pfizer Alliance and Chelsea and Westminster Foundation Trust who will sub-contract (using a Memorandum of Understanding) operations to Hounslow Clinical Commissioning Group to benefit patient care, commissioned by this CCG. This partnership will be developed under the joint working framework as defined by the DoH and A.B.P.I. [1].</p> <p>The Project will focus on evaluating and maximising opportunities to exploring and detection and diagnosis of patients at risk of Atrial Fibrillation (AF), through the deployment of a Machine Learning PULsE AI algorithm across the Primary Care Networks (PCNs). The project will be underpinned by the implementation of a targeted screening and diagnosis pathway across the local clinical network.</p> <p>Chelsea and Westminster Hospitals NHS Foundation Trust has 2 main hospital sites and a number of community services. The Trust aims to continually deliver high-quality patient care and to do so by maximising use of resources and by adopting innovative technologies and models of care. Hounslow CCG (with whom a Memorandum of Understanding will be in place) is a high performing CCG with stable leadership, a strong culture of integration and well-established services and, clinical networks. It has 46 GP (5 Primary Care Networks) member practices who deliver care to a population of over 300,000 [2].</p> <p>It is proposed that the focus of this joint working project collaboration will be to understand how Machine Learning (PULsE AI algorithm), can be successfully integrated into the existing clinical network and services to improve the identification of patients who are at risk of AF.</p>
Project Objectives:	<p>The project will focus on the delivery of the following four objectives which will underpin the delivery of the primary aim:</p> <p><b>Core Project Initiatives:</b></p> <p>Objective 1. Determine the impact and effectiveness of implementing Machine Learning PULsE AI algorithm at scale across Primary Care Networks, to identify and detect patients at risk of AF related stroke</p> <p>Objective 2. To understand the experiential learnings of GPs and their clinical teams of deploying the PULsE AI machine learning algorithm within PCNs.</p> <p>Objective 3. To understand the experience of the 'AF' patient from 'screening invite to diagnosis' at defined points within the patient pathway.</p> <p>Objective 4. Development of a best practice/resource toolkit which supports the effective deployment of PULsE AI.</p>

Job Code: CV-GB-2100252

GCMA code: PP-INT-GBR-0329

Date of prep: July 21

Patient /BMS/NHS Benefits:	<p>The expected patient benefits comprise:</p> <ul style="list-style-type: none"> <li>Improved likelihood that a patient at high risk of AF, will be identified in the CCG and subsequently diagnosed and appropriately anti-coagulated, reducing the risk of stroke</li> <li>More rapid implementation of relevant national policy, supporting a population-wide reduction in strokes locally</li> <li>Helping address the current unmet need will help reach more of the local vulnerable populations and help address health inequality</li> <li>Understanding of patient-based qualitative insights from the AF patient perspective from screening invite to diagnosis. These insights will inform a future exemplar of best practice.</li> </ul> <p>Benefit for BMS on behalf of the BMS-Pfizer Alliance: This collaboration between BMS on behalf of the BMS-Pfizer Alliance and the Trust will endeavour to evaluate the implementation of this validated algorithm and develop an understanding of future use in this and other potentially, other AF services.</p> <p>Benefits for the NHS organization also include supporting:</p> <ul style="list-style-type: none"> <li>Understanding of the impact and effectiveness of implementing machine learning algorithm at scale across (5 local Primary Care Networks), to identify and detect patients at risk of AF related stroke</li> <li>Understanding of the experiential learnings of GPs and their clinical teams, of the deploying the Pulse AI ML algorithm within PCNs.</li> <li>Understanding of the experience of the 'AF' patient from 'screening invite to diagnosis' at defined points within the patient pathway</li> <li>may provide wider learning to the local health and social care system in relation to the development and implementation of integrated service pathways.</li> </ul>
Stakeholders:	<p>Chelsea &amp; Westminster NHS Trust</p> <p>Hounslow CCG (by sub contract from C&amp;W)</p> <p>BMS on behalf of BMS-Pfizer Alliance steering/operational groups</p> <p>Imperial College Health Partners (AHSN)/ Whole Systems Integrated Care</p>
Timelines:	The project will begin from July 2021 and last for a 18 month period.

#### References:

1. ABPI, Joint Working – a toolkit for industry and the NHS; Published 4<sup>th</sup> September 2019  
<https://www.abpi.org.uk/new-medicines/working-with-the-nhs/joint-working-a-toolkit-for-industry-and-the-nhs/#9f90590c> Accessed online on the 18<sup>th</sup> April 2021.
2. NHS Hounslow Clinical Commissioning Group. Annual Report and Accounts 2019/20. Published 23<sup>rd</sup> June 2020; last accessed 10.6.21  
<https://www.hounslowccg.nhs.uk/media/155091/Hounslow-CCG-Annual-Report-and-Accounts-2019-20.PDF>

Job Code: CV-GB-2100252

GCMA code: PP-INT-GBR-0329

Date of prep: July 21

# Non-Promotional Certificate UK

**Name** UK\_IM\_JWI exec summary NW London BMS/Pfizer

**Document Number** PP-INT-GBR-0329

## NON-PROMOTIONAL ITEM CERTIFIED FOR USE

The below signatories have examined the electronic final form of this material and in their belief it complies with the Code.

Other Final Country Signatory	Name: Joyce Olekanma Signature Date: 27-Jul-2021 13:02:58 GMT+0000 Reason: Non-Promotional item certified for use
-------------------------------	---